Interviews

The investigators discuss key factors driving persistent ovarian cancer mortality disparities by age, race, and geography, and propose targeted public health and clinical interventions to address them.

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

In this first part of an interview with The American Journal of Managed Care®, Julia Rotow, MD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the critical need to test for biomarkers to afford patients the chance to benefit from recent treatment advances.

Proper placement, device understanding, and ongoing support are key to helping children and adolescents with diabetes benefit from continuous glucose monitors (CGMs), explained Marry Vuong, PharmD, BCPPS, of Perfecting Peds.

The decline in ovarian cancer mortality rates after 2003 can be attributed to advances in treatment, precision medicine, improved preventive strategies, and a reduced disease incidence, according to Muhammad Faizan, MBBS.

With inflammation being the cause of dry eye in many cases, future treatment will likely target this aspect of dry eye.

Individuals with mental illness in America continue to face socioeconomic barriers when it comes to accessing necessary care and treatment.

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, and greater competition in the B-cell maturation antigen (BCMA) bispecific antibody space.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

Hadar Avihai Lev-Tov, MD, advocates for a holistic approach to wound care, emphasizing that chronic ulcers often signal underlying systemic health issues requiring a comprehensive patient assessment to achieve effective and potentially life-saving treatment.

Michael McGuire, PharmD, reviewed Mental Health America’s recent publication on the current state of mental health in America and addressed socioeconomic barriers in access to care.

Ayodeji Adegunsoye, MD, PhD, MSc, highlights how the underrepresentation of minority populations in pulmonary fibrosis genetic studies hinders accurate disease risk prediction and broader clinical translation.

David J. Maron, MD, FASPC, president-elect of the American Society for Preventive Cardiology (ASPC), previews hot topics of interest at this year's congress and how lessons he has learned from current ASPC president Michael Shapiro, DO, FASPC, will shape his presidency set to commence next year.

Hadar Avihai Lev-Tov, MD, asserts that advancements in teledermatology and artificial intelligence (AI)–powered diagnostic tools are crucial for improving health care efficiency and patient access within managed care.

Some hospitals in New Jersey may be eligible for part of the $50 billion CMS spending on rural health care, according to State Sen Vincent Polistina (R, New Jersey).

At the 2025 Society for Pediatric Dermatology conference, Karen Vo, DO, presented research analyzing popular TikTok videos about epidermolysis bullosa, highlighting the platform’s power in raising awareness through emotional storytelling, and used her findings to advocate for early school-based mental health support and stronger, more inclusive antibullying policies for children with chronic skin conditions.

Cory Simpson, MD, PhD, assistant professor of dermatology at the University of Washington, spoke to the need for more treatment options in genetic skin conditions and the possibility of drug repurposing.

Virginia Sybert, MD, clinical professor of medical genetics at the University of Washington, discussed what dermatologists should know about molecular testing in clinical practice.

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

A review highlights the need for better research on pediatric segmental vitiligo treatments, as current options show mixed results, and at SPD 2025, Hira Ghani, DO, emphasized the importance of recognizing often-overlooked skin conditions in children.

Making sure that glands around the eyes are not blocked by poor hygiene is a vital step in mitigating symptoms of dry eye.

At the recent regional Institute for Value-Based Medicine® event in Boston, Anasuya Gunturi, MD, PhD, Lowell General Hospital, was a panelist for the discussion, “Evolving Breast Cancer Care: Addressing Unmet Needs Across the Patient Journey.”

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, said Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital.

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer treatment continuum.

State governments must have budgetary and regulatory flexibility to support health care innovation, says State Sen Vincent Polistina (R, New Jersey).

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely administer and manage them.